Specifically, Vγ9Vδ2 cells from glioblastoma (GBM) patients are expanded using zoledronate + IL2, whereupon the cells are transduced with a methylguanine DNA methyltransferase (MGMT) gene that confers resistance to temozolomide (TMZ), a chemotherapeutic standard-of-care for GBM, that by inducting genome damage may induce TCR and NKR antigens for Vγ9Vδ2 cells. This evidence concerns the gene IL2 and glioblastoma.